Objective: Evaluation of the influence of intradialytic parenteral nutrition (IDPN) in patients suffering from MalnutritionInflammation Complex Syndrome (MICS) on nutritional status, inflammation, adipocytokines and serum lipids. Subjects: Six patients with MICS were assigned to IDPN, whereas six patients matched for age, sex, body mass index (BMI) and co-morbidity without malnutrition served as controls. Patients were recruited from Outpatient Dialysis Unit, Medical University Innsbruck and from Dialysis Unit, Hospital Feldkirch. Results: In all patients with IDPN, dry body weight increased during the interventional period whereas body weight remained stable in patients without IDPN. Tumor necrosis factor (TNF)-a levels were higher in patients with MICS compared with controls at all time points. Total cholesterol, LDL-and HDL-levels significantly increased during dialysis at all time points in controls but not in patients with MICS. Albumin, C-reactive protein, interleukin-6 (IL-6), soluble interleukin-2 receptor (sIL-2R) and adipocytokines did not differ between patients and controls during the study period. Conclusions: IDPN in patients with MICS increases body weight despite not influencing inflammatory status. Furthermore, IDPN does not induce a pro-atherogenic lipid composition enhancing the risk for atherosclerosis. Thus, IDPN is a safe and effective treatment of malnutrition in patients with MICS.
Introduction
In patients with end-stage renal disease (ESRD), malnutrition is a common problem and has been claimed to influence morbidity and even mortality (Capelli et al., 1994; Kopple, 1997; Kalantar-Zadeh and Kopple, 2001; Fung et al., 2002) . Depending on the definition of malnutrition and the parameters used for the evaluation of nutritional status, the reported prevalences range between 20 and 70% (Thunberg et al., 1981; Marckmann, 1988; Owen et al., 1993 ; Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation, 2000) . Causes of malnutrition are numerous including anorexia secondary to uremia, dietary restrictions, altered metabolism, hormonal derangement and even dialysis itself (Kopple, 1978) .
Comorbid conditions such as chronic subclinical inflammation, diabetes mellitus, cardiovascular disease and peripheral vascular disease also contribute to malnutrition in patients with ESRD. Chronic subclinical inflammation, as evidenced by increased levels of pro-inflammatory cytokines and C-reactive Protein (CRP), is common in ESRD patients with malnutrition and may additionally cause progressive atherosclerotic cardiovascular disease (Bistrian et al., 1992; Pereira et al., 1994; Ikizler et al., 1999; Stenvinkel et al., 1999 Stenvinkel et al., , 2000 Zimmermann et al., 1999) .
In addition, chronic renal failure-induced dyslipidemia substantially contributes to the vascular complications observed in this population (Cofan et al., 2006) . Several studies demonstrated that lipid subfractions, including high total cholesterol (TC), high low-density lipoprotein cholesterol (LDL) and low high-density lipoprotein cholesterol (HDL), predict poor outcome in hemodialysis patients (Prichard, 2003; Chiang et al., 2005) .
Disturbances in the endocrine function of adipose tissue are of particular interest in ESRD patients because adipocytokines (i.e., leptin, adiponectin) may be involved in the high cardiovascular risk associated with this syndrome. Leptin is a signal of satiety for the central nervous system and is related to insulin and glucose metabolism (Stenvinkel et al., 1997; Mantzoros, 1999) . Adiponectin seems to play a protective role in experimental models of vascular injury and has been proposed by some investigators as a reliable marker for insulin resistance in type II diabetes (Ouchi et al., 1999; Hotta et al., 2000; Chandran et al., 2003) . High leptin and low adiponectin concentrations are common features in hemodialysis (HD) patients, especially in patients with new cardiovascular events, but their role in the pathogenesis of HD-related malnutrition is still controversial (RodriguezCarmona et al., 2000; Don et al., 2001; Zoccali et al., 2002; Shoji et al., 2005) .
Since both malnutrition and inflammation are strongly associated with each other, the term 'malnutrition-inflammation complex syndrome' (MICS) has been suggested to denote the important contribution of these conditions to ESRD outcome (Stenvinkel et al., 2000; Kalantar-Zadeh et al., 2003a) . Several approaches have been proposed as potential therapeutic interventions for the treatment of malnourished patients on chronic HD but reliable guidelines are lacking. Interventions improving nutritional status might potentially improve clinical outcome in dialysis patients (Avery-Lynch, 2006) . However, because inflammation per se is catabolic, it has been unclear whether exclusive nutritional intervention can reverse malnutrition in this setting.
The aims of this prospective study were to evaluate the influence of intradialytic parenteral nutrition (IDPN) in patients suffering from MICS on (1) nutritional status and inflammation and on (2) serum lipids and adipocytokines.
Methods

Patients
Patients were recruited from Innsbruck, Outpatient Dialysis Unit, Medical University Innsbruck and Dialysis Unit, Hospital Feldkirch, Austria. Inclusion criteria for the study included patients who have been on HD therapy for more than 6 months, with less then 100 ml/day of urine output and laboratory signs of malnutrition and chronic inflammation. Control patients were characterized by being on HD therapy for more than 6 months, with less then 100 ml/day of urine output, without laboratory signs of malnutrition and chronic inflammation.
Malnutrition was defined by normalized Protein Catabolic Rate (nPCR) o1 g/kg/day, high-sensitive C-reactive protein (hs-CRP) X0.5 mg%, serum albumin p4 g/100 ml and a body mass index (BMI) o26. To exclude patients with active infections or inflammatory disease, careful clinical examination and a focus search (chest radiograph, abdominal ultrasound, echocardiography, blood culture, otorhinolaringological examination including radiography of the sinuses, dental examination, etc.) was performed. Furthermore, patients hospitalized within 3 months before the study and those receiving steroids and/or immunosuppressive agents were excluded from the study. Eligible patients underwent a detailed counseling by a dietician and parameters were redetermined 1 month later. If the criteria were still met, they were finally included in the study.
HD was performed using a biocompatible HD membrane (polyamide, 1.7 m 2 ; PF 17L, Gambro, Hechingen, Germany), receiving an adequate dose of dialysis (single pool Kt/V 41.2, where K is the dialyzer clearance of urea in ml/min, t is the duration of the dialysis treatment in minutes, and V is the volume of distribution of urea in the body in ml), on a thrice weekly HD program. Dialysis modality, treatment time, filters used etc. were not changed during the study period. The study was approved by the Ethical Committee of the University Innsbruck and written informed consent was obtained from all study patients.
Design
This was a prospective cohort study using a matched control group. After reviewing the inclusion and exclusion criteria, six eligible patients with MICS were assigned to IDPN for a 6 months study period. The control group, matched for age, sex, BMI and co-morbidity but presenting with normal nPCR was observed for 6 months without nutritional supplementation.
When IDPN was used, infusion was started 30 min after initiation of HD. IDPN treatment was based upon existing recommendations. The solution was given at a rate of (Fresenius Kabi, Graz, Austria), 100 ml glucose 60%, 100 ml Elolipid 20% (soja bean oil 100 g/1000 ml, glycerol 25 g/1000 ml, egglecithin 12 g/1000 ml; Fresenius Kabi), 0.5 g l-carnitin and 1.25 mg vitamin E (Nephro-Mix, Fresenius Kabi). To evaluate whether appetite or spontaneous eating behavior was modified by the IDPN, nutritional intake was evaluated monthly. Patients and controls were reviewed by the study physicians on a weekly basis during the first month followed by monthly visits. Body weight and all clinically significant events such as infection, diarrhea or other complications were recorded. Blood samples were withdrawn before and at the end of HD at the beginning of the study and after 6 months to determine serum albumin, creatinine, urea, total protein, TC, LDL, HDL, triglycerides (TG), soluble interleukin-2 receptor (sIL-2), interleukin-6 (IL-6), tumor necrosis factor (TNF)-a, transferrin, CRP, leptin, soluble leptin receptor (sOb-R) and adiponectin.
Calculations
The nPCR was calculated using the formula described by Lightfoot et al. (1994) : nPCR ¼ 0.22 þ (0.036F) þ 0.251, where F is equal to Kt/V*((predialysis BUN þ postdialysis BUN)/2). BMI was calculated by using the formula BMI ¼ bodyweight (kg)/height (cm) 2 .
Analytical methods
Urea, creatinine and transferrin were measured with standard methods. Albumin was determined by immunonephelometry (Dade-Behring). Sodium, potassium and chloride with ion-selective electrodes, calcium, magnesium and phosphorus with photometry. TC was measured with CHOL (Cholesterin CHOD-PAP, Roche, Basel, Switzerland), triglycerides with TG (triglyceride GPO-PAP, Roche), HDL cholesterol was determined with HDL-C plus second generation (Roche).
hs-CRP was measured with using CRP (Latex) HS (Tinaquant, C-reaktives Protein (Latex) hoch sensitiv). Leptin was determined with Human Leptin Immunoassay (Quantikine, R&D Systems, Minneapolis, MN, USA). Human Leptin Receptor was determined with ChemiKine Human Leptin Receptor Elisa Kit (Chemicon International, Temecula, CA, USA and Canada), adiponectin with Human Adiponectin RIA Kit (Linco research, Nivelles, St Charles, MO, USA). SIL-2R was measured with sIL-2R enzyme-linked immunosorbent assay (ELISA, Beckman Coulter, Roissy, France, Cellular Communication Investigations, France), IL-6 with IL-6 enzyme amplified sensitivity immunoassay (EASIA, Biosource, Belgium) and TNF-a with TNF-a EASIA (Biosource, Nivelles, Belgium).
Statistics
Data obtained were analysed using SPSS 11.5 for Windows (SPSS Inc.). Between-groups analysis was performed using the Mann-Whitney U-test. The Wilcoxon signed ranks test for two related samples was used to compare repeated measures. Multiple comparisons were performed using Bonferroni type I error correction. A P-value o0.05 was considered statistically significant.
Results
Baseline characteristics of patients and control population are presented in Table 1 . A total of 107 patients in the Dialysis Outpatient Unit were screened for MICS. Thirtyeight patients turned out to be malnourished by having a reduced nPCR and reduced albumin concentrations with laboratory signs of inflammation (40.7%). During the screening period, 32 patients (29.9%) were excluded because an inflammatory focus was found (e.g., sinusitis, ulcers). Six patients reached the criteria and participated in the study (6.4%). Control patients were recruited from the remaining 69 patients with nPCRX1. There was one patient with diabetes in both the study and the control group. Mortality rates of patients with IDPN during the study period were 0/6, in control patients not receiving IDPN 1/6.
Nutrition parameters
In patients with IDPN, dry body weight increased from 61.777.7 to 63.978.9 kg (P ¼ 0.03) during the interventional (Table 2) . Transferrin levels were significantly lower in the interventional group compared with controls at the beginning of the study. After 6 months of IDPN, no more statistical significance between these two groups was observed ( Table 2) .
Markers of inflammation
Levels of CRP, IL-6 and sIL-2R did not differ significantly between patients and controls at the beginning of the study as well as during the interventional period (Table 2) . TNF-a levels were significantly higher in patients with MICS compared with controls at all time points (Table 2) .
Serum lipids
Serum lipids did not differ significantly between patients with MICS and controls during the study period. TC, Abbreviations: BMI, body mass index; CRP, C-reactive protein; IDPN, intradialytic parenteral nutrition; IL-6, interleukin-6; nPCR, normalized protein catabolic rate; sIL2, soluble interleukin-2 receptor; TNF-a, tumor-necrosis factor alpha.
w P values are given for the comparison of the IDPN subjects and the control group at the beginning of the study (0 months);
z P values are given for the comparison of the IDPN subjects and the control group at the end of the study (6 months). LDL cholesterol and HDL cholesterol-levels significantly increased during dialysis at the beginning and after 6 months in the control population (Table 3) . Interestingly, we could not observe this phenomenon in patients with MICS receiving IDPN; serum lipids remained stable during dialysis at all time points and during the interventional period (Table 3) .
Adipozytokines
Leptin levels were lower in patients with MICS compared with controls at the beginning of the study without reaching statistical significance (5.478.8 vs 9.4727.3 ng/ml, respectively). Interestingly, leptin levels remained stable during the interventional period in patients with IDPN as well as in patients without IDPN (3.7774.33 and 24.62736 .82 ng/ml, respectively; P40.05). Adiponectin levels did not differ significantly between patients with MICS compared with patients without MICS (53.3719.9 and 38.1716.2 mg/ml, respectively; P40.05) and remained stable in patients during IDPN after 6 months (51.6 mg/ml718.8). Furthermore, sOb-R levels did not differ significantly between patients and controls during the study period (33.9718.1 vs 29.3719.2 U/ml at the beginning and 35.6714.7 vs 37.5720.5 U/ml after 6 months; NS).
Discussion
The present study demonstrates that 6 months of IDPN in patients with MICS leads to a significant increase in body weight though not influencing inflammatory status. Furthermore, IDPN does not induce a pro-atherogenic lipid composition. To our knowledge, this study is the first to investigate the effect of IDPN in patients with MICS for 6 months. Despite rapid improvement in dialysis technology during the last 20 years, the mortality rate is still unacceptably high in ESRD patients. Chronic inflammation, as evidenced by increased levels of pro-inflammatory cytokines and CRP, is common in ESRD patients and may cause malnutrition and progressive atherosclerotic cardiovascular disease by several pathogenic mechanisms (Ikizler et al., 1999; Stenvinkel et al., 1999 Stenvinkel et al., , 2000 Zimmermann et al., 1999) . One frequently used intervention in ESRD patients suffering from malnutrition is IDPN. The benefit, however, is still under debate (Siskind and Lien, 1993; Capelli et al., 1994; Mortelmans and Vanholder, 1999; Pupim et al., 1999; Stenvinkel et al., 2000) .
In the present study, we were able to increase dry bodyweight and BMI in all patients suffering from MICS over the 6 months interventional period whereas body weight remained stable in patients without IDPN.
Low serum albumin level is a strong independent predictor of total cardiovascular mortality in HD patients (Foley et al., 1996; Stenvinkel et al., 1999; Fung et al., 2002) . As shown by a recent investigation, serum albumin does respond to IDPN in some malnourished HD patients (Avery-Lynch, 2006) . On the other hand, albumin levels were found to be low even in apparently well nourished HD patients (Nawabi et al., 1990) . This suggests that serum albumin might be an unreliable nutritional marker in dialysis patients (Steinman, 2000; Santos et al., 2003) . Since albumin is known as an acutephase protein and influenced by non nutrition-dependent factors like chronic inflammation, not surprisingly, we found stable serum albumin concentrations despite IDPN with inflammation parameters remaining elevated throughout the study period.
A low normalized protein equivalent to total nitrogen appearance, also known as nPCR, is associated with increased hospitalization and mortality in maintenance of HD patients, even when the dose of dialysis is high (KalantarZadeh et al., 2003b) . nPCR levels in our study were significantly lower in patients with MICS at the beginning of the study, tended to increase with IDPN, but remained almost stable in controls. After the 6-month interventional period, no more statistical significance between these two groups was observed, reflecting amelioration of nutritional status in patients with IDPN.
CRP is a precise and objective index of inflammatory activity and is thought to reflect accurately the generation of proinflammatory cytokines (Stenvinkel et al., 2000) . A strong relationship between malnutrition, elevated CRP levels and atherosclerosis in pre-dialysis patients was observed (Stenvinkel et al., 1999) . IL-6, a significant proatherogenic cytokine, may contribute to the development of atherosclerosis through various metabolic, endothelial and coagulant mechanisms (Yudkin et al., 2000) . TNF-a may induce net catabolism of muscle protein by stimulating branched-chain ketoacid dehydrogenase, which leads to greater oxidation of branched-chain amino acids (Nawabi et al., 1990) . Moreover, TNF-a has been shown to downregulate apolipoprotein E secretion, promote in vitro calcification of vascular cells, cause endothelial dysfunction and insulin resistance (Bhagat and Vallance, 1997; Moller, 2000; Tintut et al., 2000) . As expected, our dialysis patients fulfilling the criteria of MICS had significantly elevated TNF-a when compared with controls without MICS. Unfortunately, neither a decrease of CRP nor a significant change of IL-6, TNF-a and sIL-2R concentrations was associated with the weight gain observed in our ESRD patients with MICS treated with IDPN.
Atherosclerosis is a major concern in patients on chronic dialysis and the identification of risk factors is important for preventive and interventional strategies. Lipid abnormalities are characterized by high TC, a moderate hypertriglyceridemia, high LDL cholesterol and low HDL cholesterol, predicting poor outcomes in patients on chronic HD with high infection-related mortality (Prichard, 2003; Chiang et al., 2005) .
In this study, serum lipids did not differ significantly between patients and controls during the study period. Interestingly, TC, LDL cholesterol and HDL cholesterol-levels significantly increased consistently during dialysis at the beginning and after 6 months in the control population. In contrast, this phenomenon could not be seen in patients with MICS despite receiving IDPN. Therefore, we conclude that IDPN in patients with MICS does not alter serum lipids and does not induce an unfavorable lipid composition enhancing the risk for atherosclerosis.
Adipose tissue expresses various secretory proteins, including leptin, sOb-R and adiponectin, which may be involved in the regulation of energy expenditure, lipid metabolism and insulin resistance. The hormone leptin and its receptor (Ob-R), a member of the class I cytokine receptor family, are key homeostatic regulators of mammalian body weight. The soluble sOb-R is the major binding protein in the circulating human blood (Lammert et al., 2001) . In humans, weight gain and obesity are associated with elevated plasma leptin concentrations (Maffei et al., 1995; Considine et al., 1996) . In this study, leptin levels were not different in patients and controls corresponding to their similar distribution of body weight at the beginning. Interestingly, leptin and adiponectin levels remained unchanged at all time points during the interventional period in patients receiving IDPN despite significant weight gain. It is well known that leptin behaves as a negative rather than a positive acute phase protein in HD patients (Don et al., 2001 ). Since we could not demonstrate a reduction of CRP in our study population, this might possibly explain the lack of rising leptin levels. sOb-R levels, corresponding to leptin levels, did not change during the study period reflecting similar portion of free leptin in patients with MICS and controls.
Although the number of patients in this study is small, this is the first prospective study evaluating the influence of IDPN in patients suffering from MICS on nutritional status, inflammation, serum lipids and adipocytokines. In the present study, we were able to increase dry body weight in all patients suffering from MICS over the 6 months interventional period despite chronic inflammation, which was an unsuspected effect.
We conclude from this pilot study that IDPN in patients with MICS elevates body weight and does not exert negative effects on serum lipids and adipocytokines. Therefore, IDPN seems to be a safe and effective treatment of malnutrition in patients with MICS without enhancing the risk for atherosclerosis.
Further studies are needed to compare the effect of IDPN in patients with MICS to anti-inflammatory agents or to a combination of both in larger cohorts of patients to determine the most optimal treatment modality and improve poor outcome of patients with ESRD.
